Illumina (WBO:ILMN) Other Current Liabilities: €157 Mil (As of Mar. 2026)


WBO:ILMN Illumina Inc WBO:ILMN
67 GF Score
Price €163.26
GF Value €112.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Illumina Other Current Liabilities?

Illumina WBO:ILMN -2.29% 67 Other Current Liabilities is €157 Mil as of Mar. 2026. GuruFocus rates WBO:ILMN with a GF Score™ of 67/100 and a GF Value™ of €112.52 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Illumina's other current liabilities for the quarter that ended in Mar. 2026 was €157 Mil.

Illumina's quarterly other current liabilities increased from Sep. 2025 (€198 Mil) to Dec. 2025 (€213 Mil) but then declined from Dec. 2025 (€213 Mil) to Mar. 2026 (€157 Mil).

Illumina's annual other current liabilities increased from Dec. 2023 (€204 Mil) to Dec. 2024 (€241 Mil) but then declined from Dec. 2024 (€241 Mil) to Dec. 2025 (€213 Mil).

Illumina Other Current Liabilities Related Terms

Illumina Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Illumina's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Other Current Liabilities Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 213.29 177.47 204.49 240.66 212.65

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 183.15 185.54 197.66 212.65 157.43
WBO:ILMN
67GF Score
Illumina Inc WBO:ILMN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €157 Mil mean?
Illumina (WBO:ILMN) has a Other Current Liabilities of €157 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Illumina.
Is Illumina's Other Current Liabilities too high?
Illumina's current Other Current Liabilities is €157 Mil. Overall, Illumina has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Other Current Liabilities compare to MTD and DGX?
Illumina's Other Current Liabilities of €157 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Illumina. Illumina's current Other Current Liabilities is €157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (WBO:ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is €112.52, compared to a current price of €163.26 — trading 45.1% above its estimated fair value. The current Other Current Liabilities is €157 Mil. Illumina's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Illumina (WBO:ILMN), the current Other Current Liabilities is €157 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (WBO:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of €163.26 is trading 45.1% above its estimated GF Value™ of €112.52. GuruFocus considers Illumina to be Significantly Overvalued.

Key valuation signals for WBO:ILMN:

  • Other Current Liabilities: €157 Mil
  • GF Value™: €112.52 vs. price of €163.26 (45.1% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the WBO:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
67GF Score

Get the complete analysis for WBO:ILMN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€163.26
Price
€112.52
GF Value